Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $38.00 at Mizuho

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective reduced by Mizuho from $39.00 to $38.00 in a report released on Thursday morning, Benzinga reports. They currently have a neutral rating on the stock.

Several other research firms also recently commented on APLS. Wedbush raised their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Needham & Company LLC reiterated a “buy” rating and issued a $85.00 price target on shares of Apellis Pharmaceuticals in a research report on Friday, September 20th. UBS Group decreased their price objective on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Jefferies Financial Group restated a “buy” rating and issued a $80.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, July 31st. Finally, William Blair initiated coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating on the stock. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.41.

Apellis Pharmaceuticals Trading Down 3.3 %

NASDAQ:APLS opened at $26.68 on Thursday. Apellis Pharmaceuticals has a 12 month low of $26.28 and a 12 month high of $73.80. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. The firm’s 50 day moving average is $33.22 and its 200 day moving average is $38.51. The stock has a market capitalization of $3.24 billion, a PE ratio of -7.71 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The firm had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. During the same period in the previous year, the company posted ($1.02) earnings per share. The business’s revenue was up 110.2% on a year-over-year basis. Sell-side analysts expect that Apellis Pharmaceuticals will post -1.37 earnings per share for the current year.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. HighVista Strategies LLC grew its stake in shares of Apellis Pharmaceuticals by 4.1% during the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after buying an additional 300 shares during the last quarter. Amalgamated Bank boosted its holdings in Apellis Pharmaceuticals by 5.4% during the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after acquiring an additional 359 shares during the period. Simplicity Wealth LLC grew its position in Apellis Pharmaceuticals by 0.6% during the 2nd quarter. Simplicity Wealth LLC now owns 78,746 shares of the company’s stock worth $3,021,000 after acquiring an additional 499 shares during the last quarter. Future Financial Wealth Managment LLC purchased a new position in Apellis Pharmaceuticals in the 1st quarter worth approximately $29,000. Finally, Oppenheimer Asset Management Inc. increased its stake in Apellis Pharmaceuticals by 8.3% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock worth $511,000 after purchasing an additional 664 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).